$0.68 EPS Expected for Neptune Technologies & Bioressources Inc (NTB)

July 17, 2017 - By Marie Mckinney

 $0.68 EPS Expected for Neptune Technologies & Bioressources Inc (NTB)

Investors wait Neptune Technologies & Bioressources Inc (CVE:NTB) to report on July, 25. its quarterly earnings Neptune Technologies & Bioressources Inc’s Wall Street analysts see -2.86 % negative EPS growth, taking into account the $0.70 EPS reproted in the previous quarter, It is down 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Neptune Technologies & Bioressources Inc. is a solution well-known provider of omega-3’s and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The company has market cap of $147.24 million. The Firm is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. It currently has negative earnings. The Company’s products include Krill-Based Nutraceutical Products, including Neptune Krill Oil , OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti.

More notable recent Neptune Technologies & Bioressources Inc (CVE:NTB) news were published by: Globenewswire.com which released: “Neptune Acquires Biodroga, Creating New Growth Platform” on January 08, 2016, also Seekingalpha.com with their article: “Fiscal Year 2017 Brings New Krill Oil Development” published on August 08, 2016, Seekingalpha.com published: “Interview: Neptune Wellness Solutions CEO Jim Hamilton” on February 02, 2017. More interesting news about Neptune Technologies & Bioressources Inc (CVE:NTB) were released by: Globenewswire.com and their article: “NeuroBioPharm to be Privatized by Neptune – Enters Into Arrangement Agreement …” published on January 13, 2015 as well as Seekingalpha.com‘s news article titled: “Neptune Technologies & Bioressources’ (NEPT) CEO Jim Hamilton on Q3 2017 …” with publication date: January 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.